Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Incyte Licenses Two Microarray Patents to Merck

This story has been updated from a previous version.

NEW YORK, April 11 – Incyte Genomics said Wednesday it had licensed two patents to Merck that will allow the pharmaceutical company to manufacture microarrays using a patented non-PCR method for RNA amplification.

The patents, numbers 5,716,785 and 5,891,636, cover the use of a non-PCR-based RNA amplification technology, allowing researchers to create gene expression information by linearly increasing RNA samples from cellular mRNA.

"We are pleased that Merck is one of a growing list of companies that have recognized the value of our proprietary technology to maximize the effectiveness of their highly developed microarray based gene expression and internal microarray manufacture programs," Roy Whitfield, CEO of Incyte, said in a statement.

Incyte has exclusive licenses to the patents, which it acquired from Layton Bioscience.

Merck was not immediately available to comment on the decision to license the patents. Investment Bank Dain Rauscher Wessels said in a morning report that it expected Merck to use the licenses to produce medium- and low-density microarrays for use in its internal drug discovery and development program.

Financial terms of the deal were not disclosed.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.